Metabolism and Metabolomics of Liver in Health and Disease
Wahli, Walter
Metabolism and Metabolomics of Liver in Health and Disease - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (268 p.)
Open Access
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.
Creative Commons
English
books978-3-03943-636-1 9783039436354 9783039436361
10.3390/books978-3-03943-636-1 doi
Medicine
nonalcoholic fatty liver disease nonalcoholic steatohepatitis Fibrosis Liver biopsy Genomics Metabolomics Proteomics Transcriptomics nicotinamide NAFLD steatosis heat stress primary mouse hepatocytes metabolic profile GC-MS multivariate statistical analysis arachidonic acid docosahexaenoic acid inflammation fibrosis lipidomics mass spectrometry in vitro HepaRG sodium saccharin reference toxicants de novo lipogenesis carbohydrate response element-binding protein ChREBP diabetes glucose production glycogen glycolysis glycogen storage disease type I hexosamine pentose phosphate pathway acupuncture imflammation lipid metabolism oxidative stress metabolomics quantitative profiling 1H-NMR spectroscopy liver bile acids metabolomics rat plasma tandem mass spectrometry liquid chromatography acetaminophen hepatotoxicity biomarker premalignant alcoholic liver disease cholestasis cirrhosis NAFL NASH standard operating procedures urine blood feces tissue cells liver function nonalcoholic fatty liver liquid chromatography-mass spectrometry nuclear magnetic resonance spectroscopy metabolic pathway non-alcoholic fatty liver disease non-alcoholic steatohepatitis transcription factors metabolic stress lipid homeostasis glucose homeostasis
Metabolism and Metabolomics of Liver in Health and Disease - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 - 1 electronic resource (268 p.)
Open Access
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.
Creative Commons
English
books978-3-03943-636-1 9783039436354 9783039436361
10.3390/books978-3-03943-636-1 doi
Medicine
nonalcoholic fatty liver disease nonalcoholic steatohepatitis Fibrosis Liver biopsy Genomics Metabolomics Proteomics Transcriptomics nicotinamide NAFLD steatosis heat stress primary mouse hepatocytes metabolic profile GC-MS multivariate statistical analysis arachidonic acid docosahexaenoic acid inflammation fibrosis lipidomics mass spectrometry in vitro HepaRG sodium saccharin reference toxicants de novo lipogenesis carbohydrate response element-binding protein ChREBP diabetes glucose production glycogen glycolysis glycogen storage disease type I hexosamine pentose phosphate pathway acupuncture imflammation lipid metabolism oxidative stress metabolomics quantitative profiling 1H-NMR spectroscopy liver bile acids metabolomics rat plasma tandem mass spectrometry liquid chromatography acetaminophen hepatotoxicity biomarker premalignant alcoholic liver disease cholestasis cirrhosis NAFL NASH standard operating procedures urine blood feces tissue cells liver function nonalcoholic fatty liver liquid chromatography-mass spectrometry nuclear magnetic resonance spectroscopy metabolic pathway non-alcoholic fatty liver disease non-alcoholic steatohepatitis transcription factors metabolic stress lipid homeostasis glucose homeostasis